64,000 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Empire Financial Management Company LLC

Empire Financial Management Company LLC acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 64,000 shares of the biopharmaceutical company's stock, valued at approximately $307,000. Empire Financial Management Company LLC owned approximately 0.11% of Vanda Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at $69,000. Zacks Investment Management bought a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $74,000. Price T Rowe Associates Inc. MD increased its position in shares of Vanda Pharmaceuticals by 17.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after acquiring an additional 3,370 shares during the last quarter. SG Americas Securities LLC raised its holdings in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after acquiring an additional 5,459 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Vanda Pharmaceuticals by 28.0% during the fourth quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock valued at $161,000 after purchasing an additional 7,339 shares during the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday, April 1st. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating on the stock.

Vanda Pharmaceuticals Price Performance

VNDA traded up $0.01 during trading on Wednesday, hitting $4.44. The stock had a trading volume of 112,012 shares, compared to its average volume of 765,996. The firm has a market cap of $258.92 million, a price-to-earnings ratio of -13.88 and a beta of 0.72. The company has a 50 day moving average price of $4.56 and a 200-day moving average price of $4.67. Vanda Pharmaceuticals Inc. has a one year low of $3.85 and a one year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million during the quarter, compared to analysts' expectations of $51.00 million. As a group, sell-side analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm's stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $4.76 per share, with a total value of $47,600.00. Following the acquisition, the chief executive officer now directly owns 2,361,730 shares in the company, valued at $11,241,834.80. This represents a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased 32,000 shares of company stock valued at $151,180 over the last 90 days. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.